Introduction: Spread through air spaces (STAS) is a recently recognized pattern of invasion in lung adenocarcinoma; however, it has not yet been characterized in squamous cell carcinoma (SCC).
Introduction
Despite extensive histologic studies, [1] [2] [3] [4] [5] few clinically significant prognostic features have been discovered for lung squamous cell carcinoma (SCC). In the 2015 WHO classification, SCC is classified into keratinizing, nonkeratinizing, and basaloid subtypes. 6, 7 However, this subtyping has been shown to have limited prognostic value or other clinical significance. Suggestions that basaloid SCC has a worse prognosis have not been validated in other studies. 3, 4, [8] [9] [10] Recently, several studies demonstrated that for lung SCC, the main histologic predictors of prognosis are single-cell invasion and highgrade tumor budding. [1] [2] [3] [4] [5] On the basis of these observations, Weichert et al. developed a grading scheme for SCC that is based on combination of the two most reliable and validated prognostic makers, namely, tumor budding and nest size, and showed this to be a prognostic indicator for overall survival (OS) independent of age, sex, and stage. 4 Tumor spread through air space (STAS), a newly recognized form of invasion in lung adenocarcinoma has yet to be described in SCC. A growing number of independent studies have validated STAS to be a predictor of recurrence and survival in lung adenocarcinoma. [11] [12] [13] [14] [15] Our group showed that STAS was an independent predictor of recurrence for patients with stage I lung adenocarcinoma who underwent limited surgical resection. 11 Warth et al. examined tumors of all stages and showed that STAS was associated with both significantly reduced OS and disease-free survival for all stages of adenocarcinoma. 15 In addition, Warth et al. found significantly increased STAS in more aggressive groups of papillary adenocarcinomas. 16 STAS-like "aerogenous spread" was also described by Jin et al. in ROS1-rearranged lung adenocarcinomas associated with decreased E-cadherin expression and poor disease-free survival. 17 Shiono et al. found that in stage I adenocarcinomas, STAS correlated with OS and recurrence-free survival in both univariate and multivariate analysis.
14 Under the term free tumor clusters, Morimoto et al. demonstrated significantly reduced recurrence-free survival in STAS-positive stage I lung adenocarcinomas in addition to associations with aggressive clinical and pathologic characteristics. 12 Collectively, these studies provide convincing evidence that STAS is clinically important in lung adenocarcinoma, but the presence, frequency, and prognostic value of STAS in lung SCC has not yet been defined.
We performed a comprehensive clinicopathologic analysis using a large cohort of patients with resected lung SCC with competing risks analysis to determine whether STAS is associated with tumor aggressiveness in lung SCC.
Materials and Methods

Patient Cohorts
This retrospective study was approved by the Institutional Review Board of Memorial Sloan-Kettering Cancer Center. We reviewed all patients with solitary lung SCC who underwent surgical resection at Memorial Sloan-Kettering Cancer Center between 1999 and 2009. Clinical data were collected from the prospectively maintained Thoracic Surgery Service lung carcinoma database. All tumors were classified according to the 2015 WHO classification and grouped into three histologic subtypes (keratinizing, nonkeratinizing, and basaloid SCC) and staged according to the seventh edition of the TNM system. 6, 18 Cases with induction therapy, positive surgical margin, and other disease progression were excluded. Other aspects of these cases have been reported previously. 3, 19 Postoperative lung cancer surveillance was performed in accordance with National Comprehensive Cancer Network guidelines. 20 Recurrences were confirmed by clinical, radiological, or pathologic assessment and were classified as locoregional (local plus regional) or distant recurrence. 21 Cause of death was classified into the following 4 types: lung cancer-specific death, other cancer-specific death, non-cancer-specific death, and unknown cause. Lung cancer-specific death was defined as death due to the progression of recurrent disease of resected primary SCC. Other cancer-specific death was defined as death due to any malignant disease progression other than lung SCC. Death due to a second primary lung cancer was included in other cancer-specific death. Noncancer-specific death was defined as death due to any cause other than malignant disease.
The 445 lung SCCs included are from our previously published study in which squamous differentiation was confirmed in the poorly differentiated tumors by using immunohistochemistry. 19 
Histologic Evaluation
Tumor slides selected in this cohort were reviewed by two pathologists (S. H. L. and W. D. T.) who were blinded to patient clinical outcomes; they used an Olympus BX51 microscope (Olympus Optical Co. Ltd., Tokyo, Japan) with a standard 22-mm diameter eyepiece.
Tumor STAS was defined as small clusters of tumor cell nests within air spaces in the lung parenchyma beyond the edge of the main tumor. It was recorded as present if any STAS was identified, and the extent of STAS was recorded as defined later. The edge of the main tumor was defined as the outer border of the tumor, which is typically appreciated by low-power histologic examination ( Fig. 1A and C) . Tumor STAS was considered present when tumor cell nests were identified beyond the edge of the main tumor even if it existed only in the first alveolar layer from the tumor edge. To avoid confusion with artificially detached or floating cells during tumor dissection, tumor cells were considered only if they appeared as detached small clusters within air spaces in a continuous manner from the edge of the tumor, and the distribution was consistent with the overall configuration of the circumferential tumor edge. Haphazardly distributed fragments of tumor with sharp jagged edges were regarded as artifacts. Recognition of STAS was straightforward in most cases because the tumor had a solid growth pattern and the tumor edge had a relatively distinct border that often showed scarring and inflammation. Rarely, SCCs spread along the surface of adjacent airspaces and may undermine overlying reactive pneumocytes. This differs from STAS in which the tumor cells are present within airspaces. There may be limited opportunity to search for STAS in tumors arising within a fibrotic underlying lung parenchyma and in cases in which the submitted histologic sections did not sample the edge of the tumor including surrounding nonneoplastic lung.
STAS was distinguished from alveolar macrophages by morphologic features where tumor cells showed a high nuclear-to-cytoplasmic ratio and nuclear atypia, whereas macrophages showed small nuclei and cytoplasm that sometimes contained foamy vacuoles or carbon pigment. STAS was sometimes difficult to distinguish from tumor budding, which is defined as the presence of isolated single cancer cells or a cluster of cancer cells composed of fewer than five cells in the stroma at the outer edge of the tumor. 3, 11, 13 However, tumor budding was observed within the tumor stroma at the invasive front of the tumor, 3, 4 whereas STAS was observed within air spaces in the alveolar parenchyma beyond the edge of the tumor.
In addition, because lung specimens were not consistently inflated during processing, to account for artifactual collapse of alveolar spaces or atelectasis, the distance between tumor edge and the farthest STAS was measured in two ways: (1) by a ruler (and reported in millimeter) or (2) by the number of alveolar spaces between the tumor edge and the furthest STAS.
Necrosis in SCC was distinguished from keratinization by complete loss of cellular morphology or layering of keratin and in some cases the presence of nuclear debris.
Immunohistochemistry
Ki-67 staining was performed on tissue microarray blocks as previously reported using the standard avidin-biotin complex peroxidase technique (clone MIB-1, Immunotech, Westbrook ME, diluted at 1:100). Immunohistochemical staining to confirm squamous differentiation and exclude other histologic types was reported previously. 19 A Ki-67 labeling index of 20% or higher was classified as high and an index less than 20% was classified as low. 
Statistical Analysis
Associations between variables and the presence of STAS were analyzed with Fisher's exact test (for categorical variables) and the Wilcoxon rank sum test (for continuous variables). The primary end point was cumulative incidence of recurrence (CIR) of any type (locoregional or distant) and cumulative incidence of death (CID) of lung cancer-specific cause. The hazard of recurrence was analyzed by using competing risks methods. CIR and CID were estimated from the time of surgery by using a cumulative incidence function that accounted for death without recurrence as a competing event in the former and death due to non-cancer-specific or unknown causes as competing events in the latter. 22, 23 Patients alive and without documented recurrence at the last clinical contact were censored. As exploratory end points, we investigated the cumulative incidence of locoregional recurrence (distant recurrence as an additional competing risk) and cumulative incidence of distant recurrence (locoregional recurrence as additional competing risk). Differences in CIR or CID between groups were assessed by using Gray's test (univariable nonparametric analysis stratified by pathologic stage [p-stage]) and a Fine and Gray competing risk model. 22, 24 We investigated the relationship between clinicopathologic variables and both CIR and CID overall and separately by operation type (limited and lobectomy resection).
As a secondary outcome, OS was defined as the time from surgery to death or the last follow-up and estimated by using the Kaplan-Meier method. Univariable and multivariable analyses of OS were performed by using the Cox proportional hazards model. Multivariable models were constructed by starting with variables with p < 0.1 from univariable analyses. All p values were based on two-tailed statistical analysis and a p value less than 0.05 was considered statistically significance. Statistical analyses were conducted in R 3.0.1 (R Development Core Team) using the cmprsk and maxstat packages.
Results
Patient Clinicopathologic Characteristics
Patient clinicopathologic characteristics are shown in Table 1 . The distribution of all 445 patients with lung SCC in stages I, II, and III was 249, 131, and 65. The median age of the patients was 71.3 years (range 38.5-88.4 years). Of the 445 patients in total, 336 (76%) were older than 65 years. Two hundred sixty-five patients (60%) were male. Ninety patients (20%) received adjuvant therapy. Most patients (434 [98%]) were former or current smokers, reporting a median of 52 pack-years (range 3-252). Sixty-nine patients (16%) underwent sublobar resection and 376 (84%) underwent lobectomy. Median follow-up was 3.4 years (range 0.01-13.0 years). Of the 273 patients (61%) who died during follow-up, 
Incidence of STAS and Association between Clinicopathologic Variables and STAS
STAS was observed in 132 patients (30%). All cases showed a solid nest pattern (see Fig. 1 ). Associations between clinicopathologic factors and STAS are summarized in Table 1 
Limited and Extensive STAS
The median distance between tumor surface and farthest STAS from the tumor edge was 1.4 mm (range 0.3-4.2 mm) when measured with a ruler (Supplementary Fig. 1A ) and five (range one-15) when measured on the basis of the number of alveolar spaces ( Supplementary Fig. 1B) . When a value of three alveolar spaces was used as a potential cutoff, 15 32 patients were identified as having limited STAS (solid cell nests no more than three alveoli away from the tumor edge) whereas 100 were considered to have extensive STAS (tumor cell nests more than three alveoli away from the tumor edge).
In the univariable competing risk model for any recurrence and lung cancer-specific death (Table 2) , the subhazard ratio of limited STAS (reference: no STAS) was similar to that of extensive STAS (limited versus extensive: recurrence 2.23 versus 1.70 and lung cancerspecific death 2.39 versus 2.47, respectively). Therefore, we decided not to use extent of STAS in further multivariable competing risk regression models for any recurrence and lung cancer-specific death.
CIR of Recurrence and Lung Cancer-Specific Death by Tumor STAS all-stage patients, those with STAS had a higher incidence of any recurrence (p ¼ 0.004) ( Fig. 2A) , distant recurrence (p ¼ 0.040) (Fig. 2B ), locoregional recurrence (p ¼ 0.019) (Fig. 2C) , and lung cancer-specific death (p ¼ 0.001) (Fig. 2D ) compared with those without STAS.
In stage II to III (see Fig. 2 ), patients with STAS had a higher incidence of any and distant recurrence and lung cancer-specific death compared with those without STAS (p ¼ 0.021, p ¼ 0.014, and p ¼ 0.011, respectively) but there was no statistically significant difference in CIR for locoregional recurrence.
In stage I (see Supplementary Fig. 2 ), patients with STAS had a higher incidence of locoregional recurrence and lung cancer-specific death compared with those without STAS (p ¼ 0.028 and p ¼ 0.027, respectively) but there were no statistically significant differences in CIR for any recurrence and distant recurrence.
Univariable and Multivariable Competing Risk Regression Model for CIR, CID, and Cox Model for OS
Results from the univariable and multivariable models are presented in Table 2 and Table 3 , respectively. In the multivariable competing risk regression model for any recurrence, smoking for more than 90 pack-years and the presence of STAS were independent risk factors (p ¼ 0.043 and p ¼ 0.034, respectively), and for lung cancer-specific death, p-stage II compared with p-stage I, p-stage III compared with p-stage I, tumor budding in 10 or more high-power fields, and STAS were independent risk factors (p ¼ 0.025, p ¼ 0.009, p ¼ 0.044, and p ¼ 0.016, respectively). In the multivariable Cox model for OS, higher age, Ki-67 index of 20% or higher, and presence of single-cell invasion were independent risk factors for worse OS (p < 0.001, p ¼ 0.040, and p ¼ 0.016) but STAS was not (p ¼ 0.4).
Discussion
In this study, we demonstrated that STAS occurred in 30% of resected lung SCCs and was a significant prognostic factor for distant and locoregional recurrence. In contrast to lung adenocarcinoma, in which STAS can manifest as micropapillary clusters, solid nests, or single cells, all STAS lesions in lung SCCs consist of solid tumor cell nests. 11 Interestingly the proportion of STAS was similar (26%-36%) in all squamous histologic subtypes. This observation contrasts with lung adenocarcinoma, in which the presence of STAS was more frequent among more aggressive subtypes (papillary, micropapillary, and solid) but less so among less aggressive subtypes (lepidic and acinar). 11, 15 We found that STAS in lung SCC was associated with p-stage, lymphatic and vascular invasion, necrosis, larger nuclear diameter, increased mitoses, and high Ki-67 labeling index. The association with these characteristics of aggressive tumor behavior is similar to previous observations in lung adenocarcinoma, in which STAS correlated with lymphatic and vascular invasion and p-stage. [12] [13] [14] 25 These data show that multiple pathologic and clinical features of aggressiveness are associated with STAS in both SCC and adenocarcinoma.
STAS is an insidious pattern of tumor invasion that is not visible to pathologists on gross examination. Furthermore, STAS is easily overlooked because pathologists are not trained to look for STAS routinely. In addition, if histologic sections do not include surrounding lung parenchyma, it is impossible to look for STAS.
Optimal processing of gross specimens for STAS requires histologic sampling to include the circumferential tumor edge as well as adjacent lung parenchyma.
Identification of STAS raises important issues in the differential diagnosis. The presence of tumor cells within air spaces beyond the edge of the main tumor differs from the previously reported predominant alveolar space-filling pattern identified within the main tumor that has been reported to be associated with favorable prognosis. 26, 27 However, this pattern has not been recognized in other recent studies. 3, 4 The distinction from alveolar macrophages is less of a challenge than in adenocarcinoma because in SCC the alveolar tumor cells consist of solid nests. The cohesiveness of the solid nests of tumor cells, along with the cytologic (particularly nuclear) atypia, is morphologically different from alveolar macrophages, which are typically not cohesive, and the cytoplasm contains foamy material or carbon pigment. Rarely, one might need to perform immunohistochemistry for epithelial (i.e., AE1/AE3) and macrophage (i.e., CD68) markers to answer this question. The main challenge is to distinguish STAS from artifactual floaters. In STAS, the tumor cell nests have smooth borders and are seen in a continuous pattern from the edge of the tumor to the most distant location. Artifacts are more likely to show jagged edges and random distribution on the slides, such as isolated fragments of tumor on the tissue section.
It has been hypothesized that STAS is an ex vivo artifact caused by spreading through a knife surface. 28 The importance of distinguishing this from artifacts is appreciated by the authors who have published on this topic, and criteria for making this distinction are proposed. 13, 15, 25 STAS is morphologically different from tissue floaters and contaminant or extraneous tissues that can lead to diagnostic errors. [29] [30] [31] Stedman's Medical Dictionary defines artifact as "anything, especially in a histologic specimen or a graphic record, that is caused by the technique used and is not a natural occurrence, but is merely incidental." 32 The first part of this definition is the basis of the spreading through a knife surface hypothesis, which claims the tumor cells are spread by the force of a knife during lung resection specimen prosection. 28 Uncommonly however, surgical specimens may be encountered in a setting apart from removal of the main tumor; we have seen STAS as the predominant histologic pattern in lung adenocarcinoma specimens with no knife cut across the main tumor, suggesting this is not an ex vivo artifact. 33 Another important component of the definition of an artifact is the point that artifacts are merely incidental findings. Therefore, if STAS were just an artifact, it should have no clinical significance. However, as demonstrated in the current study of SCC and in the growing number of lung adenocarcinoma studies, STAS has consistently been shown to be a predictor of recurrence and survival. [11] [12] [13] [14] [15] [16] [17] It is argued that poorly differentiated tumor cells have a tendency toward dissociation, explaining why STAS is associated with poor prognosis. In our study of lung SCC, however, not only was STAS a predictor of cancer-specific outcomes, but it was independent of grade and multiple other histologic predictors of prognosis. Although STAS is seen more frequently in adenocarcinomas with micropapillary and solid patterns 12, 15, 16 the data suggest that STAS increases the risk for recurrence independent of the micropapillary and solid patterns. 12, 25 The risk for recurrence in limited resections for lung adenocarcinoma was 5.2 for STAS compared with 1.3 and 1.3 for micropapillary and solid patterns, respectively. 25 Perhaps one of the most important questions is whether pathologists should completely ignore the presence of STAS, particularly in the margins of limited resections. On the basis of the clinical evidence in both lung adenocarcinoma and SCC, this does not seem wise.
Our study of lung SCC showed that STAS was an independent predictor of both recurrence and cancerspecific death, but not of OS by multivariable analyses adjusting for p-stage and other pathologic prognostic variables. We found a strong correlation between STAS and high-grade morphologic patterns such as nuclear size, nuclear atypia, mitotic count and Ki-67 labeling index, suggesting that STAS is associated with tumor proliferation. Furthermore, our data showed a strong correlation of STAS with aggressive tumor behavior such as lymphatic and vascular invasion. The finding that STAS correlates with aggressive histologic features and clinical behavior is consistent with the concept that STAS represents air space invasion by the tumor cells, a pattern of invasion that is distinct from lymphovascular invasion and stroma infiltration. Histologic features such as lymphatic and vascular invasion are routinely reported as recommended by major organizations such as the College of American Pathologists. 34 As in other studies, [1] [2] [3] [4] [5] the current cohort showed that tumor budding and single-cell invasion were of prognostic importance. However, we found STAS to be independent of both lymphatic/vascular invasion and tumor budding and single-cell invasion in predicting both recurrencefree survival and cancer-specific death.
The reason why we found STAS to be significantly associated with only cancer-specific outcomes but not OS in our cohort is probably that most patients were elderly with a high risk for competing events or death from causes other than lung cancer. More than three-fourths of patients (76%) were elderly (>65 years). We found that of the 273 patients who died during follow-up, only one-third died of lung cancer whereas the remainder died of competing events or unknown cause. Our statistical method of competing risk analysis makes adjustments for this. 22, 23 We also demonstrated that STAS was independently associated with high risk for recurrence in patients undergoing lobectomy but not sublobar resection. This differs from lung adenocarcinoma, for which we showed that STAS was associated with high risk for recurrence in patients undergoing sublobar resection. 11 A likely explanation is that in our SCC cohort, few patients underwent sublobar resection in contrast to in our lung adenocarcinoma series, thus limiting the power of statistical analysis of this patient subgroup.
In conclusion, we found that STAS was present in one-third of resected lung SCCs. It was associated with aggressive clinical pathologic factors, but it was found to be an independent predictor of lung cancer-specific outcomes, and it appears to be one of the most prognostically significant histologic findings in lung SCC. Our findings of the clinical significance of STAS in lung SCC are against the concept that it is an artifact that should be ignored by pathologists. These results should be validated in independent cohorts, and interobserver agreement of recognizing STAS should be evaluated. Because we found STAS to show greater prognostic significance than lymphatic, vascular, and visceral pleural invasion, all of which are histologic features recommended to be recorded in pathology reports for lung cancer specimens, in the future, STAS may be appropriate to add to this list.
